Drug Targeting Strategy

• Active Targeting By Targeting Ligands
• Stability Improvement
• Stimuli-Responsive Controlled-Release Nanocarriers

CD Bioparticles’ services with customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms can help you to solve:

The challenges you might meet:

• Fast clearance/ fast degradation/ short circulation time of the drugs
• Unwanted immunogenicity
• The requirements for further processing the drugs, such as dispersing in, blending in or coating on another phase
• Low cell-permeability of the drugs
• Low specificity of the targeting
• High dosage required for treatment
• High side-effect of the toxic chemotherapeutic agents
• Tedious searching and conjugation of receptor-targeting-moieties
• Low stability or low activity of the drugs after various barriers within a biological system
• Highly frequent feeding of the drugs
• The requirements of sustained release, pulse release, and delayed release
• The requirements of the delivery at specific period, specific location, and specific dosage

Key features:

• Stability Improvement
  • Process of size and structure re-construction discovery
  • Physical encapsulation discovery
  • PEGylation discovery
• Active Targeting by Targeting Ligands
  • Conjugatable receptor-targeting-moiety discovery
  • Liposome discovery
  • Cell-targeting exosome engineering
  • Virus vector engineering
  • Protein Toxin engineering
  • Pro-drug engineering
• Stimuli-Responsive Controlled-Release Nanocarriers
  • Triggered-degradable, conjugation building block discovery
    • Enzyme-responsive degradable nanocarriers and building blocks
    • Chemical-responsive degradable nanocarriers and building blocks
    • Light-responsive degradable nanocarriers and building blocks
    • Electric field responsive degradable nanocarriers and building blocks
    • Shear-stress responsive degradable nanocarriers and building blocks
    • Temperature responsive degradable nanocarriers and building blocks
  • Triggered-dissociable micelles, polymersome, nanogel discovery
    • Enzyme-responsive dissociable nanocarriers and building blocks
    • Chemical-responsive dissociable nanocarriers and building blocks
    • Light-responsive dissociable nanocarriers and building blocks
    • Electric field responsive dissociable nanocarriers and building blocks
    • Shear-stress responsive dissociable nanocarriers and building blocks
    • Temperature responsive dissociable nanocarriers and building blocks
  • Photo-thermal/photo-dynamic/upconversion particle discovery
  • Magnetic particle discovery

Key benefits:

• The process of size and structure re-construction of the drugs can prolong the circulation time of the drugs
• Hydrophobic modification of the polar, small drug molecules improves the cell permeability during the passive delivery
• Hydrolyzable pro-drug prolongs the degradation time to increase the circulation time of the drugs
• Physical encapsulation systems improve the dispersion and size-regulation of the hardly dissolved drugs
• Wide coverage of the Antibodies, Aptamers, Affibody, Anticalins, and Adnectins meets your specific cell-membrane-transporter-targeting design
• Receptor-targeting-moiety modifications increase the uptake rate of the drugs
• Ready-to-use, reactive-end-group functionalized receptor-targeting-moieties simplifies your preparation procedures for labeling your drugs or your drug-loading cargos
• Drug-oriented, customized liposome production and formulation improves the delivery efficiency of the drugs, such as nucleic acids, peptides, or molecules
• Wide coverage of the stimuli-responsive building blocks will be easy for you to develop your ideal controlled delivery system
• Ready-to-use building blocks and polymer cargo system simplify the preparation of your drug delivery system and promise the reproducibility of your research data
• GMP promises the quality of products
• Analytical platforms cover from drug fabrications to in-vitro and in-vivo tests

Drug candidates:

• Easy-to-degrade API
• Hardly dissolved, hardly dispersed, crystalized drugs
• The drugs needed to be further processed, such as dispersion, coating or blending in a new phase
• Nanoparticles with low targeting efficiency and low targeting specificity
• Large molecular, peptide or nucleic acid drugs with insufficient cell-permeability
• Toxic chemotherapeutic agents
• Nanoparticles with low targeting efficiency and low targeting specificity
• Programmable delivery
• Cell specific, or tissue specific targeted delivery conditions
• Non-invasive therapy or minimally invasive therapy